COVID-19住院患者康复后3、6、9、12个月呼吸系统结局的前瞻性研究
这项前瞻性纵向队列研究纳入2020年2月1日至3月31日在武汉大学人民医院住院、未需机械通气的重症COVID-19患者,排除高血压、糖尿病、心血管疾病、癌症、慢性肺病(包括哮喘或慢阻肺)及吸烟史者,83例(61%)参与,中位年龄60岁(IQR 52-66)。出院后3、6、9、12个月随访肺功能、胸部高分辨率CT、6分钟步行距离和mMRC呼吸困难评分。多数患者肺生理和运动能力随时间改善,但12个月时20例(24%)影像学改变持续存在;DLCO中位数3个月为预计值77%(IQR 67-87)、6个月76%(68-90)、12个月88%(78-101)。多因素logistic回归显示女性与DLCO受损 odds 升高相关(OR 8.61,95%CI 2.83-26.2;p=0.0002),影像学异常与住院期间HRCT肺炎峰值评分相关(OR 1.36,95%CI 1.13-1.62;p=0.0009)。
要点
- 重症COVID-19出院患者12个月随访时20例(24%)胸部HRCT改变持续存在,多数患者肺生理和运动能力随时间改善。
- DLCO中位数在出院后3个月为预计值77%(IQR 67-87)、6个月76%(68-90)、12个月88%(78-101)。
- 多因素logistic回归显示女性与DLCO受损 odds 升高相关(OR 8.61,95%CI 2.83-26.2;p=0.0002)。
- 影像学异常与住院期间HRCT肺炎峰值评分相关(OR 1.36,95%CI 1.13-1.62;p=0.0009)。
- 作者认为需要为COVID-19患者建立统一的呼吸随访路径。
适用人群与场景
- 2020年2月1日至3月31日在武汉大学人民医院住院的重症COVID-19患者,未需机械通气。
- 排除入院时记录有高血压、糖尿病、心血管疾病、癌症、慢性肺病(包括哮喘或慢性阻塞性肺疾病)或吸烟史者。
- 排除需要插管和机械通气的患者,以避免机械通气本身影响所研究因素。
研究设计与关键结果
- 研究类型为前瞻性纵向队列研究;135例符合条件者中83例(61%)参与,中位年龄60岁(IQR 52-66)。
- 多数患者肺生理和运动能力随时间改善,但部分患者出院12个月时仍存在生理和影像学异常。
- DLCO中位数:3个月为预计值77%(IQR 67-87),6个月76%(68-90),12个月88%(78-101)。
- 出院12个月时20例(24%)患者影像学改变持续存在。
- 多因素logistic回归:女性与DLCO受损 odds 升高相关(OR 8.61,95%CI 2.83-26.2;p=0.0002)。
- 多因素logistic回归:影像学异常与住院期间HRCT肺炎峰值评分相关(OR 1.36,95%CI 1.13-1.62;p=0.0009)。
- mMRC呼吸困难评分和运动能力随时间改善。
证据类型、等级与局限
- 证据类型:前瞻性纵向队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对重症COVID-19出院患者,作者认为需要统一的呼吸随访路径。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The consequences of COVID-19 in those who recover from acute infection requiring hospitalisation have yet to be clearly defined. We aimed to describe the temporal trends in respiratory outcomes over 12 months in patients hospitalised for severe COVID-19 and to investigate the associated risk factors.
METHODS: In this prospective, longitudinal, cohort study, patients admitted to hospital for severe COVID-19 who did not require mechanical ventilation were prospectively followed up at 3 months, 6 months, 9 months, and 12 months after discharge from Renmin Hospital of Wuhan University, Wuhan, China. Patients with a history of hypertension; diabetes; cardiovascular disease; cancer; and chronic lung disease, including asthma or chronic obstructive pulmonary disease; or a history of smoking documented at time of hospital admission were excluded at time of electronic case-note review. Patients who required intubation and mechanical ventilation were excluded given the potential for the consequences of mechanical ventilation itself to influence the factors under investigation. During the follow-up visits, patients were interviewed and underwent physical examination, routine blood test, pulmonary function tests (ie, diffusing capacity of the lungs for carbon monoxide [DLCO]; forced expiratory flow between 25% and 75% of forced vital capacity [FVC]; functional residual capacity; FVC; FEV1; residual volume; total lung capacity; and vital capacity), chest high-resolution CT (HRCT), and 6-min walk distance test, as well as assessment using a modified Medical Research Council dyspnoea scale (mMRC).
FINDINGS: Between Feb 1, and March 31, 2020, of 135 eligible patients, 83 (61%) patients participated in this study. The median age of participants was 60 years (IQR 52-66). Temporal improvement in pulmonary physiology and exercise capacity was observed in most patients; however, persistent physiological and radiographic abnormalities remained in some patients with COVID-19 at 12 months after discharge. We found a significant reduction in DLCO over the study period, with a median of 77% of predicted (IQR 67-87) at 3 months, 76% of predicted (68-90) at 6 months, and 88% of predicted (78-101) at 12 months after discharge. At 12 months after discharge, radiological changes persisted in 20 (24%) patients. Multivariate logistic regression showed increasing odds of impaired DLCO associated with female sex (odds ratio 8·61 [95% CI 2·83-26·2; p=0·0002) and radiological abnormalities were associated with peak HRCT pneumonia scores during hospitalisation (1·36 [1·13-1·62]; p=0·0009).
INTERPRETATION: In most patients who recovered from severe COVID-19, dyspnoea scores and exercise capacity improved over time; however, in a subgroup of patients at 12 months we found evidence of persistent physiological and radiographic change. A unified pathway for the respiratory follow-up of patients with COVID-19 is required.
FUNDING: National Natural Science Foundation of China, UK Medical Research Council, and National Institute for Health Research Southampton Biomedical Research Centre.
TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
参考来源
- Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021. PMID: 33964245. doi:10.1016/S2213-2600(21)00174-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。